| Marcus Mayus, MD | |
|
81 Holly Hill Ln Fl 3, Greenwich, CT 06830-6071 | |
| (203) 869-5515 | |
| (203) 661-2918 |
| Full Name | Marcus Mayus |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 81 Holly Hill Ln Fl 3, Greenwich, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073734935 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 045877 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vns Westchester Chha | White plains, NY | Home health agency |
| Constellation Hospice | Orange, CT | Hospice |
| Greenwich Hospital Association - | Greenwich, CT | Hospital |
| Stamford Hospital | Stamford, CT | Hospital |
| Entity Name | Gandelman Cardiology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629264353 PECOS PAC ID: 1355437484 Enrollment ID: O20071019000351 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.
For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia to understand how this blood cancer responds to a new drug, enasidenib.
Affymetrix, Inc. today announced the launch of the GeneAtlas™ System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of research applications.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
› Verified 6 days ago
| Entity Name | Francis X Walsh Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902271729 PECOS PAC ID: 0143127472 Enrollment ID: O20160127002673 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.
For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia to understand how this blood cancer responds to a new drug, enasidenib.
Affymetrix, Inc. today announced the launch of the GeneAtlas™ System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of research applications.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
› Verified 6 days ago
| Entity Name | Murphy Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669877635 PECOS PAC ID: 4385921220 Enrollment ID: O20190404001540 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.
For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia to understand how this blood cancer responds to a new drug, enasidenib.
Affymetrix, Inc. today announced the launch of the GeneAtlas™ System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of research applications.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
› Verified 6 days ago
| Entity Name | Marcus Mayus Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780341743 PECOS PAC ID: 6507258688 Enrollment ID: O20220124000123 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.
For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia to understand how this blood cancer responds to a new drug, enasidenib.
Affymetrix, Inc. today announced the launch of the GeneAtlas™ System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of research applications.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marcus Mayus, MD 81 Holly Hill Ln Fl 3, Greenwich, CT 06830-6071 Ph: (203) 884-8420 | Marcus Mayus, MD 81 Holly Hill Ln Fl 3, Greenwich, CT 06830-6071 Ph: (203) 869-5515 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.
For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia to understand how this blood cancer responds to a new drug, enasidenib.
Affymetrix, Inc. today announced the launch of the GeneAtlas™ System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of research applications.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
› Verified 6 days ago
Dr. Nicholas Harrison Browning, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 75 Holly Hill Ln, Greenwich, CT 06830 Phone: 203-863-3400 | |
Francesca Montanari, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 77 Lafayette Pl, Greenwich, CT 06830 Phone: 203-863-3700 | |
Dr. Lisa Kurian, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Holly Hill Ln, Greenwich, CT 06830 Phone: 203-869-6960 Fax: 203-869-5103 | |
Dr. Steven Smith, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Perryridge Rd, Greenwich, CT 06830 Phone: 203-863-3911 | |
Dr. Marcelyn Carol Molloy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 75 Holly Hill Ln, Greenwich, CT 06830 Phone: 203-869-6960 Fax: 203-869-5103 | |
Dr. Alexander Delvecchio, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Holly Hill Ln, Suite 240, Greenwich, CT 06830 Phone: 203-863-4210 Fax: 203-622-1872 | |
Dr. Sunil Rana, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 49 Lake Ave Ste 2, Greenwich, CT 06830 Phone: 203-869-7704 Fax: 203-661-8596 |